Summary Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Net cash flows from operating activities:
Net income	$ 7,146	$ 5,863
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	4,413	4,176
Non-cash compensation	2,357	2,251
Deferred income taxes	(960)	(1,636)
Other non-cash adjustments to income	1,133	1,054
Changes in operating assets and liabilities:
Receivables	(4,143)	(790)
Deferred preservation costs and inventories	570	(1,365)
Prepaid expenses and other assets	(745)	(792)
Accounts payable, accrued expenses, and other liabilities	(384)	(1,025)
Net cash flows provided by operating activities	11,307	11,008
Net cash flows from investing activities:
Acquisition of Hemosphere, net of cash acquired		(17,040)
Advances under notes receivable		(1,000)
Capital expenditures	(3,241)	(2,210)
Other	(159)	(760)
Net cash flows used in investing activities	(3,400)	(21,010)
Net cash flows from financing activities:
Cash dividends paid	(2,202)	(686)
Proceeds from exercise of stock options and issuance of common stock	852	302
Repurchases of common stock	(1,523)	(3,463)
Other	(407)	(74)
Net cash flows used in financing activities	(3,280)	(3,921)
Increase (decrease) in cash and cash equivalents	4,627	(13,923)
Effect of exchange rate changes on cash	43	8
Cash and cash equivalents, beginning of period	13,009	21,705
Cash and cash equivalents, end of period	$ 17,679	$ 7,790